NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 101,409 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 101,409 shares of the business’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the sale, the insider owned 69,302 shares in the company, valued at $2,099,157.58. The trade was a 59.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Friday, March 6th, Johannes Jacob Piete Kastelein sold 94,124 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.32, for a total transaction of $2,853,839.68.
• On Thursday, March 5th, Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10.
• On Friday, February 20th, Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.31, for a total transaction of $1,605,934.11.
• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $199,500.00.

NewAmsterdam Pharma Trading Up 3.0%

Shares of NAMS opened at $30.77 on Tuesday. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $42.00. The firm has a market capitalization of $3.54 billion, a P/E ratio of -17.79 and a beta of 0.04. The firm’s 50-day moving average is $33.48 and its two-hundred day moving average is $33.32.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. Analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. The Goldman Sachs Group lifted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Stifel Nicolaus boosted their price objective on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners reissued an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, Needham & Company LLC raised their target price on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $47.10.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in NAMS. Capital World Investors boosted its stake in shares of NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after acquiring an additional 1,434,986 shares during the last quarter. Jennison Associates LLC lifted its holdings in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Duquesne Family Office LLC lifted its holdings in NewAmsterdam Pharma by 131.2% in the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $38,062,000. Finally, Adage Capital Partners GP L.L.C. raised its position in shares of NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.